Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
Not Applicable
Completed
- Conditions
- Hepatic Encephalopathy
- Registration Number
- NCT05526404
- Lead Sponsor
- Mayo Clinic
- Brief Summary
This study is being done to assess the safety and efficacy of using mobile application-based Bristol stool scale to titrate lactulose in prevention episodes of hepatic encephalopathy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Ability to provide written, informed consent.
- Currently taking lactulose daily for prevention of hepatic encephalopathy.
Exclusion Criteria
- Recent change in dosing of opioid medication.
- Previous Colorectal Surgery.
- Active diarrheal illness.
- Lack of smartphone or other smart device at home.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Achievement of daily stool goal 4 weeks Number of subject to achieve daily stool goal, determined if use of the mobile application leads to improved rates of meeting daily stool goal (3-4 stools per day of Bristol Stool Scale 3-4)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic Rochester
🇺🇸Rochester, Minnesota, United States
Mayo Clinic Rochester🇺🇸Rochester, Minnesota, United States